Abstract
We hypothesized that in essential hypertensive patients (EHs), plasma levels of pro-atherogenic adhesion molecules would be increased and related with urine albumin excretion (UAE). Thus, this study was aimed at evaluating biochemical markers of endothelial activation and their relationship with UAE in a group of patients with uncomplicated EH. In basal condition soluble forms of adhesion molecules intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1, as well as 24-h UAE were assayed. One hundred patients with essential hypertension and no diabetes or ultrasonographic evidence of atherosclerosis were included in the study. Seventy normotensive healthy subjects served as controls. EHs were first studied overall, than were divided into two subgroups: those with UAE ⩾20 mcg/min MAUs and those with UAE <20 mcg/min (non-MAUs). ICAM-1 (P<0.001) and VCAM-1 (P<0.0001) plasma concentrations were higher in EHs than in controls. Microalbuminuric EHs had greater levels of adhesion molecules than non-MAUs (ICAM-1 P=0.04; VCAM-1 P=0.02, respectively). In EHs UAE was correlated with ICAM-1 (r=0.29, P=0.003), and VCAM-1 (r=0.30, P=0.002). These associations were confirmed in multiple regression models (P=0.02 for both ICAM-1 and VCAM-1) including, along with adhesion molecules, age, body mass index and blood pressures. Our findings show that in essential hypertension there is a very early activation of endothelial adhesion molecules favouring atherosclerosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertension 2005; 23: 7–17.
Smith SJ . The role of integrin-mediated cell adhesion in health and disease: integrin based therapy in clinical medicine. Ann Intern Med 2000; 132: 333–336.
Ross R . The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–809.
Malek AM, Alper SL, Izumo S . Haemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035–2042.
Taddei S, Virdis A, Mattei P, Salvetti A . Aging and endothelial function in normotensive subjects and essential hypertensive patients. Circulation 1995; 91: 1981–1987.
Anderson TJ . Assessment and treatment of endothelial dysfunction in humans. JACC 1999; 34: 631–637.
Blann AD, Naqvi T, Waite MA, McCollum CM . Von Willebrand factor and endothelial damage in essential hypertension. J Human Hypertens 1993; 7: 107–111.
Cottone S, Vadalà A, Vella MC, Panepinto N, Cerasola G . Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensives. J Human Hypertens 1998; 12: 351–354.
Cottone S, Mulè G, Nardi E, Vadalà A, Guarneri M, Cerasola G . Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 2006; 19: 313–318.
Pedrinelli R, Giampiero O, Carmassi F, Melillo E, Dell’Omo G, Catapano G et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14–18.
Cottone S, Vadalà A, Mangano MT, Riccobene R, Mulè G, Vella MC et al. Endothelium-derived factors in microalbuminuric and non-microalbuminuric essential hypertensives. Am J Hypertension 2000; 13: 172–176.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Sharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation 2004; 110: 32–35.
2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension – Guidelines Committee. Journal of Hypertens 2003; 21: 1011–1105.
De Kossodo S, WHO Collaborative Study Group. Assaying tumour necrosis factor concentration in human serum. A WHO International Collaborative Study. J Immunol Methods 1995; 182: 107–111.
Armitage P, Berry G . Statistical Methods in Medical Research, 2nd edn, Blackwell Scientific Publications: Oxford, 1987, pp 304–312.
Anderson TJ, Gerhard MD, Meredith IT . Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71B–74B.
Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P . A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129–2135.
De Caterina R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, Morale M et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2646–2654.
Ikata J, Wakatsuki T, Oishi Y, Oki T, Ito S . Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coronary atherosclerosis. Coron Artery Dis 2000; 11: 445–449.
Blankeberg S, Rupprechy HJ, Bickel C, Peetz D, Hafner G, Tiret IJ . Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336–1342.
Malmqvist K, Wallen HN, Held C, Kahan T . Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002; 20: 1563–1569.
Rosenson RS, Koenig W . High-sensitivity CRP and cardiovascular risk in CHD patients. Curr Opin Cardiol 2002; 17: 325–331.
Blake GJ, Rifai N, Buring JE, Ridker PM . Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993–2999.
Sesso H, Buring J, Rifai N, Blage G, Cazano J, Ridker PM . C reactive protein and risk for developing hypertension. JAMA 2003; 290: 2945–2951.
Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI . Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857–861.
Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429–433.
Cerasola G, Cottone S, Mulè G, Mangano MT, Contorno A, LiVecchi M et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 15: 915–919.
Hillege HL, Fidler V, Diercks G, van Gilst W, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782.
Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al., for the investigator of HOPE Study. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA 2001; 286: 421–426.
Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969–975.
Klausen KP, Scharling H, Jensen G, Jensen JS . New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 1–5.
De Caterina R, Ghiadoni L, Taddei S, Virdis A, Almerigogna F, Basta G et al. Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertension 2001; 14: 259–266.
Bigazzi R, Bianchi S, Campese VM . Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implication. Am J Kidney Dis 1999; 34: 973–995.
Mulè G, Cottone S, Vadalà A, Volpe V, Mezzatesta G, Mongiovì R et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256: 22–29.
Klausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rassmussen B . Plasma concentration of VCAM-1 and ICAM-1 are elevated in patients with type 2 diabetes mellitus with microalbuminuria or overt nephropathy. Diabet Med 2000; 17: 644–649.
Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S . Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med 1998; 15: 661–667.
Acknowledgements
This work was supported in part by a grant from the Italian Ministry for University and Scientific Research (MURST).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cottone, S., Mulè, G., Nardi, E. et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 21, 167–172 (2007). https://doi.org/10.1038/sj.jhh.1002109
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002109
Keywords
This article is cited by
-
Vascular, cardiac and renal target organ damage associated to arterial hypertension: which noninvasive tools for detection?
Journal of Human Hypertension (2020)
-
Average real variability of 24-h systolic blood pressure is associated with microalbuminuria in patients with primary hypertension
Journal of Human Hypertension (2016)
-
Risk factors associated with urinary albumin excretion in African Americans
Journal of Human Hypertension (2011)
-
Resistin: A New Marker of Cardiorenal Risk?
American Journal of Hypertension (2010)
-
The Association of Microalbuminuria With Aortic Stiffness Is Independent of C-Reactive Protein in Essential Hypertension
American Journal of Hypertension (2009)